<DOC>
	<DOCNO>NCT00144872</DOCNO>
	<brief_summary>This open-label study evaluate efficacy safety lamotrigine ( LTG ) treatment newly-diagnosed typical absence seizure . Subjects child adolescent &lt; 13 year age . It conduct multiple site US . The study consist 4 phase : Screen Phase ( 1 week ) , Baseline Phase ( 24 hour ) , Escalation Phase ( 20 week ) Maintenance Phase ( 12 week ) . Subjects receive increase dos LTG accord dose schedule attain seizure freedom confirm hyperventilation ( HV ) clinical sign 1-hr EEG 2 consecutive weekly visit . At point , subject move 12-week Maintenance Phase . Subjects achieve seizure freedom upon reach maximum dose ( 10.2mg/kg/day ) specify dose escalation discontinue study . During Maintenance Phase , investigator use best effort maintain subject efficacious dose reach . If subject unacceptable side effect inadequate seizure control , dose study drug increase decrease specified dosing schedule . Safety assess monitor adverse event , laboratory assessment , serum lamotrigine level . Health outcomes assessment also conduct .</brief_summary>
	<brief_title>LAMICTAL ( Lamotrigine ) For The Treatment Of Absence Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy , Absence</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Inclusion criterion : Newlydiagnosed absence epilepsy never treat Antiepileptic drug ( AEDs ) . Diagnosis demonstrate one two 5minute hyperventilation test . Investigator must judge subject parent/guardian likely comply study procedure . Parent/guardian must give write informed consent . Subjects intellectually able understand concept procedure protocol must give assent also sign consent sign separate assent form . Results screen assessment judge clinically acceptable investigator indicate reason entry study would contraindicate . Exclusion criterion : Seizures result currently active , know , identifiable intracerebral lesion . Has partial generalize tonicclonic seizure . Has progressive neurological disorder define unstable least 12 week prior Screen Phase . Has psychiatric disorder require medication , past psychiatric condition judge severe require hospitalization . Has clinically significant chronic cardiac , renal , hepatic medical condition . Has condition affect absorption , distribution , metabolism , excretion drug . Is currently take psychoactive drug treat hyperactivity disorder attention deficit disorder . Has take investigational drug within 12 week prior Screen Phase . Is sexually active . Is either pregnant ( i.e. , confirm pregnancy test Screen ) breastfeeding . Has clinically significant chronic medical disorder investigator and/or GSK medical monitor determine warrant exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Absence Seizures</keyword>
	<keyword>EEG</keyword>
	<keyword>LTG</keyword>
	<keyword>Typical Absence Epilepsy</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>LAMICTAL</keyword>
</DOC>